Small Cell Lung Cancer (SCLC) Therapeutics Market Size, Trends, Growth & Outlook

Small Cell Lung Cancer (SCLC) Therapeutics Market By Type (Chemotherapy, Targeted Therapy, and Immunotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2020-2026

Industry: Life Science | Report ID: FAMI-00857 | Published on: Oct, 2020 | View: 1 | Share:         

Request Sample Enquire Before Buying Request Discount

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

  • Report Descripton
  • Table Of Content
  • Request Methodology
  • Request Customization

Global Small Cell Lung Cancer (SCLC) Therapeutics market was valued at $XX million in 2019 with a CAGR of XX% from 2020 to 2026.

Market Definition

Small cell lung cancer (SCLC) is a type of lung cancer, and it is also called oat cell cancer. Small cell lung cancer (SCLC) tends to grow and spread faster than non-small cell lung cancer (NSCLC). Small cell lung cancer (SCLC) is commonly caused by smoking. The Therapeutics treatment of small cell lung cancer (SCLC) includes chemotherapy, targeted therapy, and immunotherapy.

Global small cell lung cancer (SCLC) therapeutics market is estimated to reach $XX million by 2026; growing at a CAGR of XX% till 2026.

Market Dynamics

The rising number of small cell lung cancer (SCLC) cases is driving market demand. According to the American Society of Clinical Oncology (ASCO), in 2020, an estimated228,820 adults are expected to get diagnosed with lung cancerin the United States, which is 13% of people diagnosed with small cell lung cancer (SCLC).In Europe, small cell lung cancer (SCLC) accounts for15% to 20% of lung cancer cases. The leading cause of small cell lung cancer (SCLC) is due to tobacco smoking. According to the World Health Organization (WHO), in the United States, more than 480,000 people die each year due to cigarette smoking. Further, increasing regulatory for small cell lung cancer (SCLC) drugs is a key driving factor of the market. For instance, Jazz Pharmaceuticals plc has received the U.S. Food and Drug Administration (FDA) approval forZepzelca (lurbinectedin) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) and with disease progression on and after platinum-based chemotherapy. However, the adverse effect of small cell lung cancer (SCLC) drugs might hamper the market growth. Small cell lung cancer (SCLC) drugs can cause some side effects, including hair loss, loss of appetite or weight changes, mouth sores, nausea and vomiting, and diarrhea or constipation. In some cases, the drugs can adversely affect the blood-forming cells of the bone marrow. Moreover, increasing government initiatives for the treatment of lung cancerwould provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global small cell lung cancer (SCLC) therapeutics market is mainly classified based on type anddistribution channels. Type is segmented into Chemotherapy, Targeted Therapy, and Immunotherapy. By distribution channel,the market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Immunotherapy is expected to show significant growth in 2020, owing to the increasing collaborative clinical studies by the companies.Immunotherapy is a type of biological therapy.Immunotherapy is used for cancer treatment that helps the immune system. Moreover, increasing regulatory approval of immunotherapy for the treatment of small-cell lung cancer (SCLC) is boosting the market growth. For instance, Bristol-Myers Squibb Company has received the U.S. Food and Drug Administration (FDA) approval of Opdivo(nivolumab)for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy.

Regional Analysis

Based on geography, the global small cell lung cancer (SCLC) therapeutics market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America is expected to dominate the small-cell lung cancer (SCLC) therapeutics marketduring the forecast period, due to the rising number of small cell lung cancer (SCLC) cases. For instance, In the United States, an estimate of 29,746 adults are expected to get diagnosed with small-cell lung cancer (SCLC) in 2020. Moreover, the rise in government funding for cancer treatment and the collaboration between companies to commercialize small cell lung cancer (SCLC) drugs are some of the factors driving the market demand. For instance, G1 Therapeutics, Inc. and Boehringer Ingelheim have entered into a commercialization agreement for trilaciclib in the United States and Puerto Rico. Based on the three-year agreement, G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for thetreatmentof small-cell lung cancer (SCLC).

Competitive landscape

Key players operating in the small cell lung cancer (SCLC) therapeutics industry include Bristol-Myers Squibb, Merck, Sanofi, GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly, Teva Pharmaceutical, Takeda Pharmaceutical, Ziopharm Oncology, and Menarini.

The agreement between companies to jointly develop small cell lung cancer (SCLC) drugs, increasing investment for the development of small cell lung cancer (SCLC) drugs, increasing clinical studies, strategic acquisition of the company to increase its potential in small cell lung cancer (SCLC) therapeutics market and commercialization of regulatory approved small cell lung cancer (SCLC) drugs are some of the strategies adopted by the major companies. For instance, on September 1, 2020, AstraZeneca has received European Union approval of Imfinzi (durvalumab) for the first-line treatment of adults with extensive-stage small-cell lung cancer (SCLC) in combination with chemotherapy.

Small Cell Lung Cancer (SCLC) Therapeutics Market Key Segments:

By Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

 

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Key Global Small Cell Lung Cancer (SCLC) Therapeutics Industry Players

  • Bristol-Myers Squibb
  • Merck
  • Sanofi
  • GlaxoSmithKline
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • Teva Pharmaceutical
  • Takeda Pharmaceutical
  • Ziopharm Oncology
  • Menarini

 

What Report Provides

  • Full in-depth analysis of the parent Industry
  • Important changes in market and its dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional growth potential

Get a sample pages of this report Click here

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Small Cell Lung Cancer (SCLC) Therapeutics Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Rising Number of Small Cell Lung Cancer (SCLC) Cases
3.3.2. Increasing Regulatory for Small Cell Lung Cancer (SCLC) Drugs
3.4. Restraints
3.4.1. Adverse Effect of Small Cell Lung Cancer (SCLC) Drugs
3.5. Opportunity
3.5.1. Increasing Government Initiatives for the Treatment of Lung Cancer
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Chemotherapy
4.2.1. Market Size & Forecast
4.3. Targeted Therapy
4.3.1. Market Size & Forecast
4.4. Immunotherapy
4.4.1. Market Size & Forecast

5. Distribution Channel Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Hospital Pharmacies
5.2.1. Market Size & Forecast
5.3. Retail Pharmacies
5.3.1. Market Size & Forecast
5.4. Online Pharmacies
5.4.1. Market Size & Forecast

6. Small Cell Lung Cancer (SCLC) Therapeutics Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Small Cell Lung Cancer (SCLC) Therapeutics Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Distribution Channel
6.2.4. U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Small Cell Lung Cancer (SCLC) Therapeutics Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Distribution Channel
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Distribution Channel
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Small Cell Lung Cancer (SCLC) Therapeutics Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Distribution Channel
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Distribution Channel
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Bristol-Myers Squibb
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Bristol-Myers Squibb Product Category, Distribution Channel, and Specification
7.1.3. Bristol-Myers Squibb Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Merck
7.3. Sanofi
7.4. GlaxoSmithKline
7.5. Novartis
7.6. AstraZeneca
7.7. Eli Lilly
7.8. Teva Pharmaceutical
7.9. Takeda Pharmaceutical
7.10. Ziopharm Oncology
7.11. Menarini

Select License Type
  • Single User License $3100 USD
  • Multi-User License $4050 USD
  • Corporate User License $5100 USD

Our Clients

  • +1 518-300-1215Mon-Fri, 24Hrs
  • [email protected]We reply within an hours
  • Albany,
    NY, USA.